Generation of HPV-specific T-cells
AssigneeBaylor College of Medicine
InventorsCarlos A. Ramos, Cliona M. Rooney, Sandhya Sharma, Benjamin Hyun Joon Shin, Alex Salyer
Life of this patent
Estimating the term…
Abstract
Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.
Claims22
A method of generating or expanding a population of immune cells specific for human papillomavirus (HPV), comprising a step of stimulating a population of immune cells by culture in the presence of antigen-presenting cells (APCs) presenting a peptide of a HPV antigen, in the presence of human leucocyte antigen (HLA)-negative lymphoblastoid cell line cells (LCLs).
A method of treating or preventing a HPV-associated disease in a subject, the method comprising administering to a subject a therapeutically or prophylactically effective quantity of a population of immune cells specific for HPV generated or expanded by a method comprising a step of stimulating a population of immune cells by culture in the presence of antigen-presenting cells (APCs) presenting a peptide of a HPV antigen, in the presence of HLA-negative LCLs.
A method of treating or preventing a HPV-associated disease in a subject, the method comprising:
- (a) generating or expanding a population of immune cells specific for HPV by a method comprising a step of stimulating a population of immune cells by culture in the presence of antigen-presenting cells (APCs) presenting a peptide of a HPV antigen, in the presence of HLA-negative LCLs, and
- (b) administering a therapeutically or prophylactically effective quantity of the population of immune cells specific for HPV obtained at step (a) to a subject.
Dependencies are inferred from the claim text.